XBI: Big Pharma Can Keep The 76% Rally Going

State Street SPDR S&P Biotech ETF (XBI) is rated Buy, with 8%-14% total return expected over 6-12 months despite a 76% prior-year rally. XBI's modified equal-weight structure offers broad exposure to over 150 biotech names, benefiting from ongoing M&A and improved capital access. Recent large-cap pharma acquisitions and selective capital flows support XBI's thesis, though volatility remains high and returns are likely to moderate.

Seeking Alpha • Sep 5, 2026

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Benzinga • Sep 1, 2026

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Zacks Investment Research • Sep 1, 2026

XBI Forecast: $174.79 Tests Biotech ETF Breakout Strength

XBI approaches its 2021 high at $174.79 after a bullish flag breakout, setting up a key test between further gains and a potential consolidation.

FXEmpire • Aug 25, 2026

Analysts See Drastic Change For This Particular Part Of Healthcare

State Street SPDR S&P Biotech ETF is hovering above a buy point after breaking out.

Investors Business Daily • Aug 24, 2026

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Zacks Investment Research • Aug 24, 2026

IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?

The iShares U.S. Pharmaceuticals ETF (IHE) offers a higher dividend yield and significantly lower historical volatility than the State Street SPDR S&P Biotech ETF (XBI). XBI has outperformed IHE on a one-year basis, but XBI's growth has come with a much steeper five-year maximum drawdown.

The Motley Fool • Aug 20, 2026

XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)

State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid sector-wide optimism. XBI has surged 34% since March, outperforming XLV and SPY, fueled by M&A activity and positive clinical trial catalysts. Despite high volatility and small-cap risk, XBI's under-20x earnings multiple and diversified holdings support a constructive outlook.

Seeking Alpha • Aug 20, 2026

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

State Street SPDR S&P Biotech ETF carries a lower expense ratio of 0.35% compared to First Trust NYSE Arca Biotechnology Index Fund. FBT maintains a highly concentrated portfolio of only 30 holdings, while XBI spans 155 companies.

The Motley Fool • Aug 19, 2026

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?

VanEck Pharmaceutical ETF offers a lower-volatility profile and a higher 1.9% dividend yield compared to State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF provides broad exposure with 155 holdings, whereas VanEck Pharmaceutical ETF is concentrated in 26 major drugmakers.

The Motley Fool • Aug 18, 2026